Free Access
| Issue |
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
|
|
|---|---|---|
| Page(s) | 20 - 22 | |
| Section | M/S revues | |
| DOI | https://doi.org/10.1051/medsci/20052111s20 | |
| Published online | 15 November 2005 | |
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996; 334 : 939–45. [Google Scholar]
- GISEN. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (gruppo italiano di studi epidemiologici in nefrologia). Lancet 1997; 349 : 1857–63. [Google Scholar]
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329 : 1456–62. [Google Scholar]
- Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (Cooperate) : a randomised controlled trial. Lancet 2003; 361 : 117–24. [Google Scholar]
- Boffa JJ, Tharaux PL, Placier S, et al. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis : evidence for an endothelin-mediated mechanism. Circulation 1999; 100 : 1901–8. [Google Scholar]
- Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice : role of endothelin. J Clin Invest 1998; 101 : 2780–9. [Google Scholar]
- Fakhouri F, Placier S, Ardaillou R, et al. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001; 12 : 2701–10. [Google Scholar]
- Tharaux PL, Chatziantoniou C, Fakhouri F, et al. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36 : 330–6. [Google Scholar]
- Flamant M, Tharaux PL, Placier S et al. Epidermal growth factor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17 : 327–9. [Google Scholar]
- François H, Placier S, Parvez-Braun L, et al. Prevention of renal vascular and glomerular fibrosis by inhibiting tyrosine-kinase growth factor receptors. FASEB J 2004; 18 : 926–8. [Google Scholar]
- Fioretto P, Steffes MW, Sutherland DE, et al Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339 : 69–75. [Google Scholar]
- Boffa JJ, Tharaux PL, Dussaule JC, et al. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37 : 490–6. [Google Scholar]
- Boffa JJ, Lu Y, Placier S, et al Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14 : 1132–44. [Google Scholar]
- Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14 : 2833–42. [Google Scholar]
- Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy : a repeat biopsy study. Am J Kidney Dis 2002; 39 : 493–502. [Google Scholar]
- Warnock DG. Fabry disease : diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2005; 14 : 87–95. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.